Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 84, Issue 5, Pages 972-986
Publisher
Wiley
Online
2018-01-31
DOI
10.1111/bcp.13533
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria
- (2017) Kosuke Doki et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine
- (2017) Niloufar Marsousi et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
- (2016) L de Zwart et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters
- (2016) Aleksi Tornio et al. Expert Opinion on Drug Metabolism & Toxicology
- Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics forin vitro–in vivoextrapolation of drug metabolism and transport and considerations in selecting appropriate techniques
- (2015) Hajar Al Feteisi et al. Expert Opinion on Drug Metabolism & Toxicology
- Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations
- (2015) Nikolaos Tsamandouras et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data
- (2013) Nikolaos Tsamandouras et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide
- (2013) Manthena V. S. Varma et al. PHARMACEUTICAL RESEARCH
- Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanisticin vitro-in vivoextrapolation of oral drug absorption
- (2012) M. D. Harwood et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology
- (2012) A Rostami-Hodjegan CLINICAL PHARMACOLOGY & THERAPEUTICS
- Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations
- (2010) Z. E. Barter et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe
- (2009) J. T. Backman et al. DRUG METABOLISM AND DISPOSITION
- A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates
- (2009) Masoud Jamei et al. Drug Metabolism and Pharmacokinetics
- The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo
- (2008) A Tornio et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started